Quoin Pharmaceuticals(QNRX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

QNRX Quoin Pharmaceuticals

Pre-Market Trading 11-26 06:14:42 EST

0.5950

+0.0100

+1.71%

High0.6120	Low0.5900	Vol71.24K
Open0.5990	D1 Closing0.5850	Amplitude3.76%
Mkt Cap3.00M	Tradable Cap2.29M	Total Shares5.05M
T/O42.67K	T/O Rate1.85%	Tradable Shares3.86M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

{"stockData":{"symbol":"QNRX","market":"US","secType":"STK","nameCN":"Quoin Pharmaceuticals","latestPrice":0.595,"timestamp":1732568400000,"preClose":0.585,"halted":0,"volume":71240,"delay":0,"floatShares":3856399,"shares":5049720,"eps":-2.636215,"marketStatus":"Pre-Market Trading","change":0.01,"latestTime":"11-26 06:14:42 EST","open":0.599,"high":0.612,"low":0.59,"amount":42671.40644,"amplitude":0.037607,"askPrice":0.7598,"askSize":100,"bidPrice":0.58,"bidSize":150,"shortable":3,"etf":0,"ttmEps":-2.636215,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1732631400000},"marketStatusCode":1,"adr":0,"adrRate":1,"exchange":"NASDAQ","adjPreClose":0.6,"postHourTrading":{"tag":"盘后","latestPrice":0.6,"preClose":0.595,"latestTime":"19:56 EST","volume":235,"amount":141.3832,"timestamp":1732582579806},"volumeRatio":0.6785572489292058},"requestUrl":"/m/hq/s/QNRX/tweets","defaultTab":"tweets","newsList":[{"id":"2483397830","title":"QNRX: International Sites Participating in QRX003 NS Study, Studying QRX003 for Additional Diseases, in Younger Populations","url":"https://stock-news.laohu8.com/highlight/detail?id=2483397830","media":"Zacks Small Cap Research","labels":["Company Corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483397830?lang=en_us&edition=fundamental","pubTime":"2024-11-12 19:00","pubTimestamp":1731409200,"startTime":"0","endTime":"0","summary":"U.S. and International Sites participating in QRX003 NS study, Expanding to study QRX003 for additional indications and in younger patient populations. Quoin Pharmaceuticals  provided a business update last week. The company implemented a number of measures during the quarter to move lead asset QRX003 forward. For instance, Quoin initiated testing of the safety and efficacy of QRX003 in a pediatric patient with Netherton Syndrome . NS is a rare inherited genetic disease for which there is currently no approved treatment or cure. This initiative addresses multiple QNRX’s objectives, including studying QRX003 in pediatric patient populations. Treating pediatric patients is important, as early treatment is critical to managing the disease. The company also commenced measures to expand clinical activities on QRX003 internationally. Separately, management raised its stake in QNRX shares, which we view as a positive indicator of its optimism about the company’s prospects.Two active late stag","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/qnrx-international-sites-participating-qrx003-110000612.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"Company Corporation","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["QNRX","NS","BK4144","BK4139","BK4590","NORD"],"gpt_icon":1},{"id":"2482413648","title":"Quoin Pharmaceuticals at Risk of Nasdaq Delisting Amidst Financial Challenges","url":"https://stock-news.laohu8.com/highlight/detail?id=2482413648","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2482413648?lang=en_us&edition=fundamental","pubTime":"2024-11-09 14:01","pubTimestamp":1731132064,"startTime":"0","endTime":"0","summary":"Quoin Pharmaceuticals Ltd (QNRX) has disclosed a new risk, in the Share Price & Shareholder Rights category. Quoin Pharmaceuticals Ltd faces a sign...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/quoin-pharmaceuticals-at-risk-of-nasdaq-delisting-amidst-financial-challenges?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/quoin-pharmaceuticals-at-risk-of-nasdaq-delisting-amidst-financial-challenges?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4112","IE00BGHQF748.EUR","SQQQ","IE00B3QW5Z07.USD","LU2210150020.SGD","LU2095319765.USD","BK4588","MNQmain","LU2210149790.SGD","QLD","PSQ","QID","IE00B64PRP62.GBP","QNRX",".IXIC","NDAQ","IE00BKPKM429.USD","BK4585","NQmain","BK4139","TQQQ"],"gpt_icon":0},{"id":"2482755438","title":"Promising Developments and Financial Stability Propel Quoin Pharmaceuticals’ Buy Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2482755438","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2482755438?lang=en_us&edition=fundamental","pubTime":"2024-11-09 01:35","pubTimestamp":1731087330,"startTime":"0","endTime":"0","summary":"Naz Rahman, an analyst from Maxim Group, has initiated a new Buy rating on Quoin Pharmaceuticals (QNRX). Naz Rahman has given his Buy rating due to...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/promising-developments-and-financial-stability-propel-quoin-pharmaceuticals-buy-rating?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/promising-developments-and-financial-stability-propel-quoin-pharmaceuticals-buy-rating?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["QNRX"],"gpt_icon":0},{"id":"2481852139","title":"Quoin Pharmaceuticals Ltd reports results for the quarter ended in September 30 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2481852139","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481852139?lang=en_us&edition=fundamental","pubTime":"2024-11-08 01:20","pubTimestamp":1731000057,"startTime":"0","endTime":"0","summary":"Quoin Pharmaceuticals Ltd reports results for the quarter ended in September 30 - Earnings Summary  Quoin Pharmaceuticals Ltd QNRX.OQ reported a quarterly adjusted loss of 47 cents per share for the q","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241107:nL8N3ME3BJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["QNRX"],"gpt_icon":0},{"id":"2481907792","title":"Quoin Pharmaceuticals GAAP EPS of -$0.47 misses by $0.01","url":"https://stock-news.laohu8.com/highlight/detail?id=2481907792","media":"seekingalpha","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481907792?lang=en_us&edition=fundamental","pubTime":"2024-11-07 21:26","pubTimestamp":1730985996,"startTime":"0","endTime":"0","summary":"Quoin Pharmaceuticals press release (NASDAQ:QNRX): Q3 GAAP EPS of -$0.47  misses by $0.01. Quoin had approximately $10.3 million in cash, cash equivalents and marketable securities as of Sept. 30, 2024. This is expected to fund the Company’s operations into late 2025.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/news/4260613-quoin-pharmaceuticals-gaap-eps-of-0_47-misses-0_01","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"seekingalpha","symbols":["QNRX"],"gpt_icon":0},{"id":"2481904310","title":"Quoin Had Approximately $10.3M In Cash, Cash Equivalents And Marketable Securities As Of Sept. 30, 2024. This Is Expected To Fund The Company's Operations Into Late 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2481904310","media":"Benzinga","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481904310?lang=en_us&edition=fundamental","pubTime":"2024-11-07 21:06","pubTimestamp":1730984782,"startTime":"0","endTime":"0","summary":"Quoin Had Approximately $10.3M In Cash, Cash Equivalents And Marketable Securities As Of Sept. 30, 2024. This Is Expected To Fund The Company's Operations Into Late 2025","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.benzinga.com/general/biotech/24/11/41805404/quoin-had-approximately-10-3m-in-cash-cash-equivalents-and-marketable-securities-as-of-sept-30-20","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","QNRX"],"gpt_icon":0},{"id":"2481904345","title":"Quoin Pharmaceuticals Q3 2024 GAAP EPS $(0.47) Misses $(0.46) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2481904345","media":"Benzinga","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481904345?lang=en_us&edition=fundamental","pubTime":"2024-11-07 21:05","pubTimestamp":1730984739,"startTime":"0","endTime":"0","summary":"Quoin Pharmaceuticals (NASDAQ:QNRX) reported quarterly losses of $(0.47) per share which missed the analyst consensus estimate of $(0.46) by 2.17 percent.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/24/11/41805389/quoin-pharmaceuticals-q3-2024-gaap-eps-0-47-misses-0-46-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"Quoin Pharmaceuticals Q3 2024 GAAP EPS $(0.47) Misses $(0.46) Estimate","news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["QNRX"],"gpt_icon":0},{"id":"2481901488","title":"Press Release: Quoin Pharmaceuticals Provides Corporate Update and Announces Third Quarter 2024 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2481901488","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481901488?lang=en_us&edition=fundamental","pubTime":"2024-11-07 21:00","pubTimestamp":1730984400,"startTime":"0","endTime":"0","summary":"Further Expansion of International Reach for Netherton Syndrome Clinical Trials. Significant Insider Share Purchases by the Entire Management Team. ASHBURN, Va., Nov. 07, 2024  -- Quoin Pharmaceuticals Ltd.  , a clinical-stage, specialty pharmaceutical company focused on developing and commercializing novel treatments for rare and orphan diseases, today provides a business update and announces financial results for the three and nine months ended Sept. 30, 2024.-- Peeling Skin Syndrome  Study: In August, Quoin announced the planned. initiation of an investigator-led clinical study in New Zealand for. QRX003 in pediatric patients with Peeling Skin Syndrome. This rare. genetic condition currently has no approved treatments or cures. The. first clinical site and patient have been identified, and Quoin is. actively evaluating additional clinical sites in other countries.-- Insider Share Purchases: In September, Quoin's CEO, COO and CFO made. -- Netherton Syndrome Clinical Trials Expansion:","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["QNRX","BK4139","WRD"],"gpt_icon":0},{"id":"2481250949","title":"Quoin initiates clinical testing of QRX003 in pediatric NS trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2481250949","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481250949?lang=en_us&edition=fundamental","pubTime":"2024-11-05 21:15","pubTimestamp":1730812551,"startTime":"0","endTime":"0","summary":"Quoin Pharmaceuticals (QNRX) announced that it has initiated the testing of the safety and efficacy of QRX003 in a young child with Netherton Syndr...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/quoin-initiates-clinical-testing-of-qrx003-in-pediatric-ns-trial?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/quoin-initiates-clinical-testing-of-qrx003-in-pediatric-ns-trial?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["NS","BK4144","BK4590","BK4139","QNRX"],"gpt_icon":0},{"id":"2481062585","title":"Quoin Pharmaceuticals Initiates Clinical Testing of Lead Product in Pediatric Netherton Syndrome Patient","url":"https://stock-news.laohu8.com/highlight/detail?id=2481062585","media":"GlobeNewswire","labels":["Product Release"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481062585?lang=en_us&edition=fundamental","pubTime":"2024-11-05 21:00","pubTimestamp":1730811600,"startTime":"0","endTime":"0","summary":"Clinical Assessment Is Being Performed on a Pediatric Patient at Children’s Health Ireland in Dublin First Evaluation of QRX003 in a Pediatric Patient Second Clinical Site to Open in Spain with Potent","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/11/05/2974879/0/en/Quoin-Pharmaceuticals-Initiates-Clinical-Testing-of-Lead-Product-in-Pediatric-Netherton-Syndrome-Patient.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"Product Release","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4590","BK4139","BK4144","NS","QNRX"],"gpt_icon":1},{"id":"2480696750","title":"Quoin Pharmaceuticals to Announce Third Quarter 2024 Financial Results on Thursday, November 7, 2024","url":"https://stock-news.laohu8.com/highlight/detail?id=2480696750","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2480696750?lang=en_us&edition=fundamental","pubTime":"2024-11-01 04:05","pubTimestamp":1730405100,"startTime":"0","endTime":"0","summary":"ASHBURN, Va., Oct.  31, 2024  (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a clinical stage specialty pharmaceutical company focused on rare and orphan dis","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/10/31/2973023/0/en/Quoin-Pharmaceuticals-to-Announce-Third-Quarter-2024-Financial-Results-on-Thursday-November-7-2024.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","QNRX"],"gpt_icon":1},{"id":"2477335897","title":"BRIEF-Quoin Pharmaceuticals Announces Further International Expansion Of Ongoing Clinical Trials For Netherton Syndrome","url":"https://stock-news.laohu8.com/highlight/detail?id=2477335897","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2477335897?lang=en_us&edition=fundamental","pubTime":"2024-10-22 20:14","pubTimestamp":1729599272,"startTime":"0","endTime":"0","summary":"Oct 22  - Quoin Pharmaceuticals Ltd   :   * QUOIN PHARMACEUTICALS ANNOUNCES FURTHER INTERNATIONAL EXPANSION OF ONGOING CLINICAL TRIALS FOR NETHERTON SYNDROME   * QUOIN PHARMACEUTICALS LTD - EXPANDS NETHERTON SYNDROME STUDIES TO UK   * QUOIN PHARMACEUTICALS LTD - PREPARING TO OPEN ADDITIONAL SITES IN WESTERN AND EASTERN EUROPESource text for Eikon:    Further company coverage:    ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ETH","QNRX","BK4139"],"gpt_icon":1},{"id":"2477010338","title":"Quoin Pharmaceuticals Announces Further International Expansion of Ongoing Clinical Trials for Netherton Syndrome","url":"https://stock-news.laohu8.com/highlight/detail?id=2477010338","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2477010338?lang=en_us&edition=fundamental","pubTime":"2024-10-22 20:00","pubTimestamp":1729598400,"startTime":"0","endTime":"0","summary":"Two Additional Clinical Sites to be Opened in the United Kingdom. These clinical sites, as well as the previously announced site in Saudi Arabia, will operate under the auspices of Quoin’s open Investigational New Drug  application with the US Food and Drug Administration. Quoin is also in advanced stage of preparation for the opening of additional sites in several other Western European countries and is concluding a feasibility study in multiple Eastern European countries with both territories having available cohorts of patients with NS.Quoin Pharmaceuticals Ltd. is a clinical stage specialty pharmaceutical company focused on developing and commercializing therapeutic products that treat rare and orphan diseases. We are committed to addressing unmet medical needs for patients, their families, communities and care teams. Quoin’s innovative pipeline comprises five products in development that collectively have the potential to target a broad number of rare and orphan indications, inclu","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/RnVbzAeH3fAA0IdxS31DCA--~B/aD03Njg7dz0xNTAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/06790a224a8bf4eaff6ec2d82577b006","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/RnVbzAeH3fAA0IdxS31DCA--~B/aD03Njg7dz0xNTAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/06790a224a8bf4eaff6ec2d82577b006"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/quoin-pharmaceuticals-announces-further-international-120000210.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4205","BK4141","BK4528","LU1878469433.USD","PI","BK4590","BK4144","BK4233","NS","QNRX","WRD","UK","BK4139"],"gpt_icon":1},{"id":"2466196627","title":"Quoin Pharmaceuticals announces insider share purchases","url":"https://stock-news.laohu8.com/highlight/detail?id=2466196627","media":"seekingalpha","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2466196627?lang=en_us&edition=fundamental","pubTime":"2024-09-09 21:08","pubTimestamp":1725887303,"startTime":"0","endTime":"0","summary":"Quoin Pharmaceuticals  has announced that its CEO, Michael Myers, and COO, Denise Carter, have recently made significant purchases of the Co.’s ADSs, signaling their confidence in the company’s growth and direction. On Sept. 3 and 4, 2024, Michael Myers, CEO of Quoin Pharmaceuticals, acquired a total of 37,894 ADSs at prices ranging from $0.619 to $0.7974 per ADS.  Similarly, COO Denise Carter acquired a total of 37,735 ADSs between September 3 and 4, 2024, at prices between $0.6253 and $0.7965 per ADS. QNRX +5% premarket to $0.81.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/news/4147992-quoin-pharmaceuticals-announces-insider-share-purchases","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"seekingalpha","symbols":["QNRX","BK4139"],"gpt_icon":1},{"id":"2466642321","title":"Press Release: Quoin Pharmaceuticals Announces Insider Share Purchases by Co-Founders CEO and COO","url":"https://stock-news.laohu8.com/highlight/detail?id=2466642321","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2466642321?lang=en_us&edition=fundamental","pubTime":"2024-09-09 20:30","pubTimestamp":1725885000,"startTime":"0","endTime":"0","summary":"Purchases Signal Leadership Confidence and Commitment to Company. ASHBURN, Va., Sept. 09, 2024  -- Quoin Pharmaceuticals , a clinical stage, specialty pharmaceutical company focused on developing and commercializing novel treatments for rare and orphan diseases, today announced that its Chief Executive Officer, Michael Myers, and Chief Operating Officer, Denise Carter, have recently made significant purchases of the company's American Depositary Shares , signaling their confidence in the company's growth and direction.On September 3 and 4, 2024, Michael Myers, CEO of Quoin Pharmaceuticals, acquired a total of 37,894 ADSs at prices ranging from $0.619 to $0.7974 per ADS. Similarly, COO Denise Carter acquired a total of 37,735 ADSs between September 3 and 4, 2024, at prices between $0.6253 and $0.7965 per ADS. These insider purchases reflect the leadership's strong confidence in Quoin's growth trajectory and commitment to delivering long-term value to shareholders as the company advances","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1992135472.HKD","BK4588","LU2211815571.USD","LU1992135399.USD","LU2272731600.USD","BK4585","GB00BDT5M118.USD","BK4139","QNRX","LU2272731782.SGD","COO","BK4198"],"gpt_icon":1},{"id":"2461341205","title":"QNRX: Assessing QRX003 For Multiple Conditions; Opening International Netherton Syndrome Clinical Sites","url":"https://stock-news.laohu8.com/highlight/detail?id=2461341205","media":"Zacks Small Cap Research","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2461341205?lang=en_us&edition=fundamental","pubTime":"2024-08-22 19:05","pubTimestamp":1724324700,"startTime":"0","endTime":"0","summary":"International expansion of clinical trial sites for QRX003 study, beginning with Saudi Arabia…Quoin Pharmaceuticals  has made numerous strides advancing its portfolio of assets to treat various rare and orphaned diseases. The company’s lead asset is QRX003, which currently is being evaluated for the treatment of Netherton Syndrome  in two active studies that are being conducted concurrently in the U.S. The company also intends to expand its clinical trial sites for QRX003 internationally under the open FDA Investigational New Drug  application. A center in Saudi Arabia will be the first international location participating in the study. It is currently treating several NS patients who will now be eligible to participate in Quoin’s studies. The company has hired an experienced CRO  to manage its clinical development activities in Saudi Arabia.Peeling Skin Syndrome is a rare autosomal disease that has no approved treatment or cure. Quoin believes it has the opportunity to achieve the fir","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/qnrx-assessing-qrx003-multiple-conditions-110500949.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4144","QNRX","NS","BK4139","NORD","BK4590"],"gpt_icon":1},{"id":"2458516229","title":"Maxim Group Sticks to Their Buy Rating for Quoin Pharmaceuticals (QNRX)","url":"https://stock-news.laohu8.com/highlight/detail?id=2458516229","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2458516229?lang=en_us&edition=fundamental","pubTime":"2024-08-10 00:27","pubTimestamp":1723220825,"startTime":"0","endTime":"0","summary":"Maxim Group analyst Naz Rahman reiterated a Buy rating on Quoin Pharmaceuticals (QNRX – Research Report) yesterday. The company’s shares opened tod...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/maxim-group-sticks-to-their-buy-rating-for-quoin-pharmaceuticals-qnrx?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/maxim-group-sticks-to-their-buy-rating-for-quoin-pharmaceuticals-qnrx?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["QNRX"],"gpt_icon":0},{"id":"2458341446","title":"Quoin Pharmaceuticals reports Q2 results","url":"https://stock-news.laohu8.com/highlight/detail?id=2458341446","media":"seekingalpha","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2458341446?lang=en_us&edition=fundamental","pubTime":"2024-08-09 00:00","pubTimestamp":1723132815,"startTime":"0","endTime":"0","summary":"Quoin Pharmaceuticals press release  (NASDAQ:QNRX): Q2 Loss per ADS of -$0.39.\nQuoin had approximately $12.6M in cash, cash equivalents and marketable securities as of June 30, 2024, which is expected to fund the company’s operations into late 2025.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/news/4137384-quoin-pharmaceuticals-reports-q2-results","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"seekingalpha","symbols":[".IXIC","SQQQ","BK4139","QLD","NQmain","PSQ","QNRX","TQQQ","MNQmain","QID"],"gpt_icon":1},{"id":"2457390979","title":"Quoin Pharmaceuticals Q2 2024 GAAP EPS $(0.39) Beats $(0.62) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2457390979","media":"Benzinga","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2457390979?lang=en_us&edition=fundamental","pubTime":"2024-08-08 20:32","pubTimestamp":1723120357,"startTime":"0","endTime":"0","summary":"Quoin Pharmaceuticals Q2 2024 GAAP EPS $(0.39) Beats $(0.62) Estimate","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/24/08/40251444/quoin-pharmaceuticals-q2-2024-gaap-eps-0-39-beats-0-62-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"Quoin Pharmaceuticals Q2 2024 GAAP EPS $(0.39) Beats $(0.62) Estimate","news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["QNRX"],"gpt_icon":0},{"id":"2457318889","title":"Quoin Pharmaceuticals: Cash, Cash Equivalents & Marketable Securities as of June 30, 2024, Expected to Fund Co's Operations Into Late 2025.","url":"https://stock-news.laohu8.com/highlight/detail?id=2457318889","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2457318889?lang=en_us&edition=fundamental","pubTime":"2024-08-08 20:30","pubTimestamp":1723120201,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20240808:nTUA5CMS0C:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["QNRX","BK4139"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.quoinpharma.com","stockEarnings":[{"period":"1week","weight":-0.0083},{"period":"1month","weight":-0.2636},{"period":"3month","weight":-0.0167},{"period":"6month","weight":-0.15},{"period":"1year","weight":-0.8699},{"period":"ytd","weight":-0.8787}],"compareEarnings":[{"period":"1week","weight":0.0159},{"period":"1month","weight":0.0319},{"period":"3month","weight":0.0641},{"period":"6month","weight":0.1358},{"period":"1year","weight":0.3124},{"period":"ytd","weight":0.2571}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Quoin Pharmaceuticals, Ltd., a clinical stage specialty pharmaceutical company, focuses on the development and commercialization of therapeutic products for rare and orphan diseases. Its lead product is QRX003, a topical lotion to treat Netherton Syndrome (NS). The company is also developing QRX004 for the treatment of recessive dystrophic epidermolysis bullosa; QRX007 to treat NS; and QRX008 for the treatment of scleroderma. It has a research agreement with Queensland University of Technology; a license agreement with Skinvisible Inc.; consulting agreements with Axella Research LLC; and a Master Service Agreement with Therapeutics Inc. The company was founded in 2018 and is based in Ashburn, Virginia. Quoin Pharmaceuticals, Ltd. operates as a subsidiary of Skinvisible, Inc.","yearOnYearQuotes":[{"month":1,"riseRate":0.333333,"avgChangeRate":-0.110793},{"month":2,"riseRate":0,"avgChangeRate":-0.363342},{"month":3,"riseRate":0.333333,"avgChangeRate":-0.207129},{"month":4,"riseRate":0.333333,"avgChangeRate":-0.200377},{"month":5,"riseRate":0.333333,"avgChangeRate":-0.086228},{"month":6,"riseRate":0.333333,"avgChangeRate":-0.122896},{"month":7,"riseRate":0.666667,"avgChangeRate":0.046056},{"month":8,"riseRate":0.333333,"avgChangeRate":-0.164394},{"month":9,"riseRate":0,"avgChangeRate":-0.26963},{"month":10,"riseRate":0.333333,"avgChangeRate":0.108579},{"month":11,"riseRate":0.25,"avgChangeRate":-0.188348},{"month":12,"riseRate":0,"avgChangeRate":-0.227728}],"exchange":"NASDAQ","name":"Quoin Pharmaceuticals","nameEN":"Quoin Pharmaceuticals"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Quoin Pharmaceuticals(QNRX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Quoin Pharmaceuticals(QNRX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Quoin Pharmaceuticals,QNRX,Quoin Pharmaceuticals股票,Quoin Pharmaceuticals股票老虎,Quoin Pharmaceuticals股票老虎国际,Quoin Pharmaceuticals行情,Quoin Pharmaceuticals股票行情,Quoin Pharmaceuticals股价,Quoin Pharmaceuticals股市,Quoin Pharmaceuticals股票价格,Quoin Pharmaceuticals股票交易,Quoin Pharmaceuticals股票购买,Quoin Pharmaceuticals股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Quoin Pharmaceuticals(QNRX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Quoin Pharmaceuticals(QNRX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction